Risk factors

Anika Therapeutics (ANIK) risk factors

Item 1A of every Anika Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open ANIK in Gloom →
Anika Therapeutics' chart, financials and news, free in your browser.Open ANIK in Gloom →
  • FY2025 10-K risk factors
    43 risks3 new1 dropped8 reworded

    Anika Therapeutics faces regulatory delays for its Hyalofast product following an FDA deficiency letter.

    Filed Mar 03, 2026
  • FY2024 10-K risk factors
    41 risks

    Revenue heavily relies on J&J MedTech, which accounted for 57% of 2024 revenue for Monovisc and Orthovisc.

    Filed Mar 17, 2025